Some of the major players operating in the market are AstraZeneca, GSK plc, Cipla, Teva Pharmaceutical Industries Ltd., Sanofi, Avillion LLP, Novartis AG, CHIESI Farmaceutici S.p.A., Boehringer ...

A ceremony marking the start of construction on AstraZeneca's new small molecule drug factory is held in Wuxi, East China's Jiangsu province, on May 8. [Photo provided to chinadaily.com.cn] ...

AstraZeneca Pharma shares rose on receiving nod from the CDSCO, to import for sale and distribution of Benralizumab 30 mg/ml ...

Bangalore: AstraZeneca Pharma India Limited has received regulatory approval from the Central Drugs Standard Control ...

Through this approval, Benralizumab is indicated as an add-on treatment for adult patients with relapsing or refractory eosinophilic granulomatosis with polyangiitis (EGPA).

Copyright: © 2025 The Author(s). Published by Elsevier Ltd.

The "Semaglutide Market Size, Share & Trends Analysis Report by Product (Ozempic, Wegovy, Rybelsus), Application (Type 2 Diabetes Mellitus, Obesity), Route of Administration, Distribution Channel, ...

Patients received Dato-DXd 6 mg/kg once every 3 weeks. The primary end point was objective response rate (ORR) by blinded independent central review. Secondary end points included duration of response ...

AstraZeneca AZN stock has declined 6.4% in the past three months. Although AstraZeneca faces its share of challenges, a significant portion of this price decline is attributed to broader market ...

Tezepelumab demonstrated clinically relevant benefits in specific inflammatory subtypes of COPD - an historically underserved ...

AstraZeneca will present the latest clinical and real-world ... the underlying mechanisms that drive a broader range of inflammatory conditions: • Fasenra (benralizumab): Demonstrating Fasenra's ...

AstraZeneca has a better P/E ratio of 27.25 than the aggregate P/E ratio of 27.19 of the Pharmaceuticals industry. Ideally, one might believe that AstraZeneca Inc. might perform better in the ...